tm logo
Trademark Search
SYNTHORX

View On IC.GC.CA

SYNTHORX
REGISTERED

on 09 Aug 2024

Last Applicant/ Owned by

SYNTHORX INC.

11099 N. Torrey Pines Road, Suite 190La Jolia, CA 92037

US

Serial Number

1945232 filed on 08th Feb 2019

Registration Number

TMA1250377 registered on 09th Aug 2024

Registration expiry Date

09th Aug 2034

Correspondent Address

SCOTIA PLAZA40 KING STREET WEST40th FLOORTORONTO

ONTARIO

CA

M5H3Y2

SYNTHORX

Trademark usage description

protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunologic d Read More

Classification Information

Class [005]
Protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunologic diseases and disorders namely, autoimmune diseases and disorders, oncology including immuno-oncology, cardiovascular diseases, and metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, and infectious diseases, namely, urinary tract infections; protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics namely, pharmaceutical preparations for use in immunologic diseases and disorders namely, autoimmune diseases and disorders, including rheumatism, oncology including immuno-oncology, pulmonology, namely, respiratory diseases, gastroenterology, endocrine diseases, namely, glucagonoma, dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, urology, gynecology, namely, disorders relating to sexual reproduction and fertility, infectiology, namely, anti-viral agents, ophthalmology, hepatological diseases and disorders, neurological disorders, namely, brain injury, spinal cord injury, seizure disorders, and geriatric diseases, namely, arthritis, osteoporosis, Dementia, Alzheimer's Disease, and Parkinson's Disease; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, anti-infectives, pain killers, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunologic diseases and disorders namely, autoimmune diseases and disorders, including rheumatism, oncology including immuno-oncology, pulmonology, namely, respiratory diseases, gastroenterology, endocrine diseases, namely, glucagonoma, dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, urology, gynecology, namely, disorders relating to sexual reproduction and fertility, infectiology, namely, anti-viral agents, ophthalmology, hepatological diseases and disorders, neurological disorders, namely, brain injury, spinal cord injury, seizure disorders, and geriatric diseases, namely, arthritis, osteoporosis, Dementia, Alzheimer's Disease, and Parkinson's Disease.

Classification kind code

11

Class [042]
Medical research; scientific research in the field of DNA; pharmaceutical research and development; laboratory research services in the field of pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, geriatrics, genetics and phenomics, pathology and forensics, proteomics, and veterinary medicine and diagnostics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents.

Classification kind code

11

Mark Details

Serial Number

1945232

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 42
on 01st May 2024		Advertised
Submitted for opposition 27
on 03rd Apr 2024		Approval Notice Sent
Submitted for opposition 26
on 03rd Apr 2024		Approved
Submitted for opposition 22
on 02th Dec 2022		Search Recorded
Submitted for opposition 20
on 02th Dec 2022		Examiner's First Report
Submitted for opposition 135
on 02th Aug 2021		Amendment to Application
Submitted for opposition 48
on 04th Mar 2021		Agent Changed
Submitted for opposition 31
on 13th Feb 2019		Formalized
Submitted for opposition 30
on 08th Feb 2019		Filed
Submitted for opposition 1
on 08th Feb 2019		Created